News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
730,198 Results
Type
Article (41333)
Company Profile (265)
Press Release (688583)
Multimedia
Podcasts (91)
Webinars (20)
Section
Business (204835)
Career Advice (2031)
Deals (35579)
Drug Delivery (128)
Drug Development (81507)
Employer Resources (173)
FDA (16503)
Job Trends (14979)
News (346796)
Policy (32750)
Tag
2027 BioCapital Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (3)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2593)
Accelerated approval (46)
Adcomms (26)
Allergies (170)
Alliances (49579)
ALS (210)
Alzheimer's disease (1782)
Antibody-drug conjugate (ADC) (440)
Approvals (16875)
Artificial intelligence (652)
Autoimmune disease (280)
Automation (54)
Bankruptcy (362)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (219)
Biotechnology (175)
Bladder cancer (186)
Brain cancer (70)
Breast cancer (743)
Cancer (5755)
Cardiovascular disease (466)
Career advice (1723)
Career pathing (41)
CAR-T (328)
CDC (56)
Celiac Disease (3)
Cell therapy (885)
Cervical cancer (47)
Clinical research (70736)
Collaboration (2032)
Company closure (5)
Compensation (1381)
Complete response letters (78)
COVID-19 (2740)
CRISPR (107)
C-suite (1106)
Cystic fibrosis (151)
Data (7759)
Decentralized trials (3)
Denatured (27)
Depression (159)
Dermatology (83)
Diabetes (584)
Diagnostics (6916)
Digital health (54)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (314)
Drug pricing (200)
Drug shortages (31)
Duchenne muscular dystrophy (280)
Earnings (91914)
Editorial (66)
Employer branding (21)
Employer resources (152)
Events (119356)
Executive appointments (1075)
FDA (20191)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (16)
Frontotemporal dementia (34)
Funding (1704)
Gene editing (232)
Generative AI (55)
Gene therapy (712)
GLP-1 (1049)
Government (4728)
Grass and pollen (6)
Guidances (408)
Healthcare (18987)
HIV (79)
Huntington's disease (56)
IgA nephropathy (96)
Immunology and inflammation (285)
Immuno-oncology (91)
Indications (189)
Infectious disease (3077)
Inflammatory bowel disease (216)
Inflation Reduction Act (14)
Influenza (136)
Intellectual property (288)
Interviews (319)
IPO (16666)
IRA (50)
Job creations (3646)
Job search strategy (1430)
JPM (58)
Kidney cancer (19)
Labor market (98)
Layoffs (561)
Leadership (38)
Legal (7953)
Liver cancer (99)
Longevity (32)
Lung cancer (757)
Lymphoma (427)
Machine learning (59)
Management (59)
Manufacturing (1029)
MASH (183)
Medical device (13919)
Medtech (14037)
Mergers & acquisitions (20152)
Metabolic disorders (1484)
mRNA (203)
Multiple sclerosis (187)
NASH (17)
Neurodegenerative disease (411)
Neuropsychiatric disorders (105)
Neuroscience (3278)
Neurotech (1)
NextGen: Class of 2026 (6521)
Non-profit (4530)
Now hiring (77)
Obesity (695)
Opinion (285)
Ovarian cancer (218)
Pain (250)
Pancreatic cancer (294)
Parkinson's disease (356)
Partnered (33)
Patents (592)
Patient recruitment (665)
Peanut (62)
People (59540)
Pharmaceutical (59)
Pharmacy benefit managers (32)
Phase 1 (22048)
Phase 2 (31162)
Phase 3 (23191)
Pipeline (8468)
Policy (313)
Postmarket research (2568)
Preclinical (9392)
Press Release (64)
Prostate cancer (293)
Psychedelics (54)
Radiopharmaceuticals (319)
Rare diseases (1064)
Real estate (5968)
Recruiting (70)
Regulatory (25356)
Reports (56)
Research institute (2413)
Resumes & cover letters (353)
Rett syndrome (38)
RNA editing (21)
RSV (88)
Schizophrenia (176)
Series A (286)
Series B (211)
Service/supplier (11)
Sickle cell disease (111)
Special edition (23)
Spinal muscular atrophy (165)
Sponsored (48)
Startups (3638)
State (2)
Stomach cancer (18)
Supply chain (126)
Tariffs (87)
The Weekly (62)
Vaccines (1088)
Venture capital (107)
Weight loss (447)
Women's health (124)
Worklife (20)
Date
Today (211)
Last 7 days (924)
Last 30 days (3430)
Last 365 days (30240)
2026 (11941)
2025 (30170)
2024 (35211)
2023 (40072)
2022 (51174)
2021 (55707)
2020 (54082)
2019 (46537)
2018 (35017)
2017 (32107)
2016 (31479)
2015 (37551)
2014 (31318)
2013 (26347)
2012 (28570)
2011 (29264)
2010 (27328)
Location
Africa (741)
Alabama (92)
Alaska (7)
Arizona (347)
Arkansas (14)
Asia (39646)
Australia (6499)
California (13133)
Canada (3725)
China (1322)
Colorado (563)
Connecticut (571)
Delaware (400)
Europe (85788)
Florida (1963)
Georgia (420)
Hawaii (3)
Idaho (62)
Illinois (1044)
India (88)
Indiana (596)
Iowa (23)
Japan (529)
Kansas (130)
Kentucky (50)
Louisiana (40)
Maine (75)
Maryland (1576)
Massachusetts (9370)
Michigan (359)
Minnesota (708)
Mississippi (6)
Missouri (144)
Montana (33)
Nebraska (29)
Nevada (140)
New Hampshire (84)
New Jersey (3454)
New Mexico (29)
New York (3433)
North Carolina (1665)
North Dakota (9)
Northern California (6574)
Ohio (393)
Oklahoma (23)
Oregon (41)
Pennsylvania (2639)
Puerto Rico (29)
Rhode Island (50)
South America (1112)
South Carolina (85)
South Dakota (2)
Southern California (5180)
Tennessee (209)
Texas (2084)
United States (46331)
Utah (392)
Vermont (1)
Virginia (316)
Washington D.C. (80)
Washington State (1052)
West Virginia (4)
Wisconsin (124)
Wyoming (2)
730,198 Results for "morphogenesis inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioMidwest
Morphogenesis, Inc. Announces Corporate Rebranding to TuHURA Biosciences, Inc. and Provides a Business Overview
Morphogenesis, Inc., a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, announced its corporate rebranding and provided a business overview.
December 14, 2023
·
6 min read
BioMidwest
Morphogenesis, Inc to Present at the Virtual Investor Summer Spotlight Series
Morphogenesis, Inc. announced that Dr. James Bianco, Chief Executive Officer of Morphogenesis will present at the Virtual Investor Summer Spotlight Series on Tuesday, July 11, 2023 at 3:00 PM ET.
July 6, 2023
·
1 min read
Biotech Bay
Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Morphogenesis, Inc. (“Morphogenesis”) and CohBar, Inc. (NASDAQ: CWBR) (“CohBar”), today announced that Morphogenesis’ abstract has been accepted for poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023 in Chicago, IL.
May 30, 2023
·
10 min read
Business
Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting - May 30, 2023
Morphogenesis, Inc. and CohBar, Inc. today announced that Morphogenesis’ abstract has been accepted for poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
May 30, 2023
·
10 min read
BioMidwest
Morphogenesis, Inc. Biomarker Analysis Data from IFx-Hu2.0 in Melanoma Refractory to Anti-PD1-Based Therapies Demonstrates Ability to Overcome Primary Resistance to Checkpoint Inhibitors and Trigger an Innate Immune Response
Morphogenesis, Inc. announced positive biomarker analysis data from its first-in-human study evaluating IFx-Hu2.0 for patients with melanoma refractory to anti-PD1-based therapies.
November 8, 2023
·
4 min read
Business
Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0
Morphogenesis, Inc. and CohBar, Inc. (CWBR) (“CohBar”), today announced positive initial results from an exploratory analysis of anti-tumor responses to rechallenge with an ICI following protocol directed IFx-Hu2.0 therapy among patients with advanced MCC or cSCC who exhibited primary resistance to ICIs.
June 5, 2023
·
13 min read
Business
CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy
CohBar, Inc. and Morphogenesis, Inc. today announced that they have entered into a definitive agreement for an all-stock transaction forming a company combining expertise and resources to advance a late-stage oncology pipeline.
May 23, 2023
·
14 min read
Business
Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced MCC and Cutaneous Squamous Cell Carcinoma (cSCC)
Morphogenesis, Inc. and CohBar, Inc., announced positive initial results from an exploratory analysis of anti-tumor responses to rechallenge with an ICI following protocol directed IFx-Hu2.0 therapy among patients with advanced MCC or cSCC who exhibited primary resistance to ICIs.
June 5, 2023
·
12 min read
Deals
Morphogenesis Inc. Acquires TυHURA Biopharma’s First-in-Class Antibody Drug Conjugates (ADCs) Technology Designed to Overcome Acquired Resistance to Cancer Immunotherapy
Morphogenesis Inc., a Phase 3 clinical stage biopharmaceutical company developing novel personalized cancer vaccines, announced today that it has entered into a definitive asset purchase agreement, in a stock for stock transaction, to acquire TυHURA’s novel ADCs targeting MDSCs to modulate tumor microenvironment immunosuppression.
March 28, 2023
·
5 min read
Press Releases
Zivo Bioscience, Inc. Announces Transition to OTCID Marketplace
May 13, 2026
·
3 min read
1 of 73,020
Next
